In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin
- 12 June 1995
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 279 (2-3) , 241-249
- https://doi.org/10.1016/0014-2999(95)00168-k
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Seven-day antinociceptive effect of a sustained release vapreotide formulationNeuroReport, 1994
- RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic ratsEuropean Journal of Pharmacology, 1993
- Modulation of neurotransmission in airwaysPhysiological Reviews, 1992
- Cigarette smoke-induced airway oedema is blocked by the NK1 antagonist, CP-96,345European Journal of Pharmacology, 1991
- Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345British Journal of Pharmacology, 1991
- Long-lasting antinociceptive effect of RC-160, a somatostatin analog, in mice and ratsEuropean Journal of Pharmacology, 1991
- Inflammatory Mediators Involved in Antigen-induced Airway Microvascular Leakage in Guinea PigsAmerican Review of Respiratory Disease, 1988
- Peripheral and spinal mechanisms of nociception.Physiological Reviews, 1987
- SOMATOSTATIN, A POTENT ANALGESICThe Lancet, 1984
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982